Abstract
Natalizumab is a humanized IgG4κ monoclonal antibody that is a selective adhesion molecule inhibitor, which prevents adhesion of leukocytes to endothelial cells. It is the first monoclonal antibody approved by the FDA for the treatment of relapsing-remitting MS. This article will review the mechanism of action and clinical role of this agent.
Cite
CITATION STYLE
APA
Selewski, D. T., Shah, G. V., Segal, B. M., Rajdev, P. A., & Mukherji, S. K. (2010, October). Natalizumab (Tysabri). American Journal of Neuroradiology. https://doi.org/10.3174/ajnr.A2226
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free